Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Zimmermann

Showing results (141-150 of 279) with videos related to

Pageof 28
Sort By:
Genes, Chromosomes & Cancer|June 28, 2020
Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocolMareike Jung, Maximilian Schieck, Winfried Hofmann, et al.
Haematologica|September 9, 2021
Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphomaFabian Knörr, Martin Zimmermann, Andishe Attarbaschi, et al.
Cancer Research|September 5, 2019
Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate CancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Haematologica|August 26, 2017
The role of constitutive activation of FMS-related tyrosine kinase-3 and <i>NRas/KRas</i> mutational status in infants with <i>KMT2A</i>-rearranged acute lymphoblastic leukemiaHenning Fedders, Ameera Alsadeq, Juliane Schmäh, et al.
BMC Cancer|June 20, 2018
MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κBDavid M Cordas Dos Santos, Juliane Eilers, Alfonso Sosa Vizcaino, et al.
Blood|June 19, 2009
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocolsMartin Stanulla, Elke Schaeffeler, Anja Möricke, et al.
Pediatric Blood & Cancer|April 4, 2017
Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhoodJuliane Schmäh, Birthe Fedders, Renate Panzer-Grümayer, et al.
Cancer Research|October 3, 2014
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Haematologica|August 6, 2013
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolGunnar Cario, Peter Rhein, Rita Mitlöhner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group ReportJanina Salzburg, Birgit Burkhardt, Martin Zimmermann, et al.
Pageof 28

Showing results (141-150 of 279) with videos related to

Sort By:
Pageof 28
Genes, Chromosomes & Cancer|June 28, 2020
Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP-BFM acute lymphoblastic leukemia protocolMareike Jung, Maximilian Schieck, Winfried Hofmann, et al.
Haematologica|September 9, 2021
Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphomaFabian Knörr, Martin Zimmermann, Andishe Attarbaschi, et al.
Cancer Research|September 5, 2019
Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate CancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Haematologica|August 26, 2017
The role of constitutive activation of FMS-related tyrosine kinase-3 and <i>NRas/KRas</i> mutational status in infants with <i>KMT2A</i>-rearranged acute lymphoblastic leukemiaHenning Fedders, Ameera Alsadeq, Juliane Schmäh, et al.
BMC Cancer|June 20, 2018
MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κBDavid M Cordas Dos Santos, Juliane Eilers, Alfonso Sosa Vizcaino, et al.
Blood|June 19, 2009
Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocolsMartin Stanulla, Elke Schaeffeler, Anja Möricke, et al.
Pediatric Blood & Cancer|April 4, 2017
Molecular characterization of acute lymphoblastic leukemia with high CRLF2 gene expression in childhoodJuliane Schmäh, Birthe Fedders, Renate Panzer-Grümayer, et al.
Cancer Research|October 3, 2014
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Haematologica|August 6, 2013
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolGunnar Cario, Peter Rhein, Rita Mitlöhner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group ReportJanina Salzburg, Birgit Burkhardt, Martin Zimmermann, et al.
Pageof 28